B-Cell Non-Hodgkin's Lymphoma: Epidemiology Forecast to 2027
Summary
Non-Hodgkin's lymphoma (NHL) refers to a group of cancers that develop in the lymphatic system. In NHL, the patient's immune system is affected by the uncontrollable growth of malignant white blood cells, resulting in the body's inability to fight infections and other diseases. NHL accounts for 90% of all malignant lymphomas. NHL is one of the most prevalent hematologic cancers in adults and is more commonly diagnosed in developed countries. B-cell lymphomas are the most common form of NHL diagnosed in developed countries, making up approximately 80-85% of NHL cases in the US.
GlobalData epidemiologists used age- and sex-specific diagnosed incidence and prevalence rates to forecast the diagnosed incident and prevalent ......
|
$3995 |
|
Post-Traumatic Stress Disorder: Epidemiology Forecast to 2028
Summary
Post-Traumatic Stress Disorder (PTSD) is a psychiatric disorder that can occur in people who have experienced or witnessed a traumatic event such as a natural disaster, a serious accident, a terrorist act, war/combat, rape, or other violent personal assault (American Psychiatric Association, 2018). PTSD affects as many as one in four people who experience traumatic events, and contributes to marked functional disability, health impairment, and social dysfunction. People with PTSD may relive the event via intrusive memories, flashbacks, and nightmares; avoid anything that reminds them of the trauma; and have anxious feelings they didn't have before (North, Hong and Downs, 2018).
GlobalData epidemiologists utilized nati......
|
$3995 |
|
Partnerships, Licensing, Investments and M&A Deals and Trends for April 2019 in Pharmaceuticals
Summary
GlobalData's "Partnerships, Licensing, Investments and M&A Deals and Trends for April 2019 in Pharmaceuticals", report is an essential source of data and trend analysis on partnerships, licensing, mergers and acquisitions (M&As) and financings in the pharmaceuticals industry. The report provides detailed information on partnership and licensing transactions, M&As, equity/debt offerings, private equity, and venture financing registered in the pharmaceuticals industry in April 2019. The report portrays detailed comparative data on the number of deals and their value in the last six months, subdivided by deal types, various therapy areas, and geographies. Additionally, the report provides......
|
$1000 |
|
Allergic Diseases: Pipeline Offers Novel Approaches to Treat Increasingly Prevalent Conditions, with Strong Presence of Cytokine Mediators Among First-in-Class Products
Summary
An allergy or allergic disease is a condition that arises from an adverse reaction to an exogenous antigen, a substance that invokes an immunological response. These conditions are extremely common. The number of people diagnosed with allergic diseases is rising rapidly on a global scale, which is attributable to factors such as population growth and increased urbanization and pollution. In addition, for a minority of these patients, allergic reactions can be severe, debilitating, or even life-threatening.
Despite this high disease burden, treatment options are limited for many conditions and patients often recei......
|
$6995 |
|
Digital Therapeutics and Their Impact on Healthcare
Summary
Due to increasing levels in healthcare spending combined with declining R&D returns, digital therapeutics (DTx) represent a new way of treatment in which digital systems are used as regulatory?approved, to treat medical conditions as prescribed therapeutic interventions. There is a growing number of DTx developed on the market today as well as pipeline products in development following internationally-recognized, quality, design and manufacturing standards. DTx will provide a new approach to treatment and disease management in which patients have the possibility to learn more about their conditions and treatment options and this will lead to manage their own health and disease conditions.
This report provides an overview of cur......
|
$7995 |
|
Pharmaceutical & Healthcare Quarterly Deals Analysis M&A and Investment Trends - Q1 2019
Summary
GlobalData's "Pharmaceutical & Healthcare Quarterly Deals Analysis M&A and Investment Trends - Q1 2019", report is an essential source of data and trend analysis on partnerships, licensing, mergers and acquisitions (M&As) and financings in the pharmaceuticals industry. The report provides detailed information on partnership and licensing transactions, M&As, equity/debt offerings, private equity, and venture financing registered in the pharmaceuticals industry in Q1 2019. The report portrays detailed comparative data on the number of deals and their value in the last five quarters, subdivided by deal types, various therapy areas, and geographies. Additionally, the report provides information o......
|
$1500 |
|
CountryFocus: Healthcare, Regulatory and Reimbursement Landscape - Italy
Summary
GlobalData, the industry analysis specialist, has released its latest report, "CountryFocus: Healthcare, Regulatory and Reimbursement Landscape - Italy". The report is an essential source of information and analysis on the healthcare, regulatory and reimbursement landscape in Italy. It identifies the key trends in the healthcare market and provides insights into the demographic, regulatory, reimbursement landscape and healthcare infrastructure of Italy. Most importantly, the report provides valuable insights into the trends and segmentation of the pharmaceutical and medical device markets. It is built using data and information sourced from proprietary databases, secondary research, and in-house analysis by ......
|
$1995 |
|
Partnerships, Licensing, Investments and M&A Deals and Trends for 2018 in Pharmaceuticals
Summary
GlobalData's "Partnerships, Licensing, Investments and M&A Deals and Trends for 2018 in Pharmaceuticals", report is an essential source of data and trend analysis on partnerships, licensing, mergers and acquisitions (M&As) and financings in the pharmaceuticals industry. The report provides detailed information on partnership and licensing transactions, M&As, equity/debt offerings, private equity, and venture financing registered in the pharmaceuticals industry in 2018. The report portrays detailed comparative data on the number of deals and their value in the last five years, subdivided by deal types, various therapy areas, and geographies. Additionally, the report provides information on th......
|
$3500 |
|
Obesity: Gut Hormone Receptors Retain Commercial Prominence
Summary
Obesity is a chronic and potentially fatal disease. The most prevalent metabolic disorder affecting people today, obesity requires multidisciplinary continuing treatment. Despite the market's clinical and regulatory challenges, the obesity pipeline is robust and contains a high level of diversity in both molecule types and molecular targets, which is in line with its multifactorial etiology. The primary concern within the market is the need for medications that adequately address the unmet clinical needs in the overweight and obese population, namely efficacious and safe therapies. This report assesses first-in-class innovation across the obesity pipeline.
Scope
- The obesity pipeline is robust and contains a high leve......
|
$6995 |
|
Dermatomycoses Global Clinical Trials Review, H1, 2019
Summary
GlobalData's clinical trial report, "Dermatomycoses Global Clinical Trials Review, H1, 2019" provides an overview of Dermatomycoses clinical trials scenario. This report provides top line data relating to the clinical trials on Dermatomycoses. Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type. Report also provides prominent drugs for in-progress trials (based on number of ongoing trials). GlobalData Clinical Trial Reports are generated using GlobalData's proprietary database - Pharma eTrack Clinical trials database. Clin......
|
$2500 |
|
